Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 76 55 15 73
Acinar Cell Adenoma 12 73
Acinic Cell Adenoma 12
Adenomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 44 D000236
NCIt 50 C2855 C4196

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to pleomorphic adenoma and pituitary adenoma, prolactin-secreting. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Aldosterone synthesis and secretion. The drugs Ticlopidine and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 An adenoma (from Greek αδένας, adeno-, \"gland\" + -ώμα, -oma, \"tumor\") (/ˌædɪˈnoʊmə/; plural adenomas... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 844)
# Related Disease Score Top Affiliating Genes
1 pleomorphic adenoma 34.7 PLAG1 PLAGL1 PLAGL2
2 pituitary adenoma, prolactin-secreting 34.7 AIP GNAS MEN1 PRL
3 growth hormone secreting pituitary adenoma 34.5 AIP GNAS PRL
4 sebaceous adenoma 34.5 MLH1 MSH2
5 silent pituitary adenoma 34.4 AIP MEN1
6 functioning pituitary adenoma 34.3 AIP MEN1 PRL
7 parathyroid adenoma 34.2 CCND1 CDC73 MEN1 RET
8 colorectal adenoma 34.2 APC CTNNB1 KRAS MLH1 MSH2
9 periampullary adenoma 34.2 APC KRAS
10 null pituitary adenoma 34.1 AIP MEN1
11 polyposis syndrome, hereditary mixed, 1 33.9 APC MLH1
12 hyperparathyroidism 1 33.7 CDC73 MEN1
13 acromegaly 33.6 AIP GNAS MEN1 PRL
14 mutyh-associated polyposis 33.1 APC KRAS SMAD4
15 familial adenomatous polyposis 1 32.9 APC CTNNB1
16 hyperparathyroidism 2 with jaw tumors 32.8 CCND1 CDC73 MEN1 RET
17 parathyroid carcinoma 32.7 CCND1 CDC73 MEN1 RET
18 mismatch repair cancer syndrome 32.6 APC CTNNB1 MLH1 MSH2
19 multiple endocrine neoplasia, type iia 32.6 CDC73 MEN1 RET
20 multiple endocrine neoplasia, type i 32.5 CDC73 GNAS MEN1 PRL RET
21 familial adenomatous polyposis 32.4 APC CCND1 CTNNB1 KRAS MLH1 MSH2
22 colorectal cancer 31.6 APC CCND1 CTNNB1 GNAS KRAS MLH1
23 hyperthyroidism 31.3 GNAS PRL TSHR
24 pituitary tumors 31.3 AIP GNAS MEN1 PRL
25 mccune-albright syndrome 31.3 APC GNAS PRL
26 carney complex variant 31.3 AIP GNAS MEN1
27 peutz-jeghers syndrome 31.3 APC CTNNB1 SMAD4
28 primary hyperparathyroidism 31.1 CCND1 CDC73 MEN1 PRL RET
29 hyperparathyroidism 31.0 CDC73 MEN1 RET
30 hyperparathyroidism 3 30.9 CDC73 MEN1
31 familial colorectal cancer 30.8 APC MLH1 MSH2
32 hypothyroidism 30.8 GNAS PRL RET TSHR
33 colorectal adenocarcinoma 30.7 CTNNB1 KRAS MLH1 MSH2
34 colon adenocarcinoma 30.7 CTNNB1 KRAS MLH1
35 colitis 30.7 CTNNB1 MLH1 MSH2 SMAD4
36 adenocarcinoma 30.6 APC CCND1 CTNNB1 GNAS KRAS MLH1
37 fibrous dysplasia 30.5 APC GNAS PRL
38 lynch syndrome 30.5 APC CCND1 CTNNB1 KRAS MLH1 MSH2
39 hepatoblastoma 30.4 APC CTNNB1 PLAG1
40 gastric cancer 30.3 APC CCND1 CTNNB1 KRAS MLH1 SMAD4
41 thyroid cancer 30.1 APC CCND1 CTNNB1 GNAS KRAS RET
42 differentiated thyroid carcinoma 30.1 KRAS RET TSHR
43 attenuated familial adenomatous polyposis 30.1 APC MSH2
44 pancreas adenocarcinoma 29.9 CCND1 CTNNB1 GNAS KRAS SMAD4
45 gastric adenocarcinoma 29.8 APC CCND1 CTNNB1 GNAS KRAS MLH1
46 thyroid carcinoma, familial medullary 29.8 KRAS MEN1 RET
47 breast cancer 28.0 APC CCND1 CTNNB1 GNAS KRAS MLH1
48 adrenal adenoma 12.3
49 pituitary adenoma 12.3
50 hepatic adenomas, familial 12.3

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 58)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.86 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.86 CTNNB1 KRAS SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.86 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.86 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.86 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.86 KRAS
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.86 MEN1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.86 MLH1 PLAG1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.86 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.86 PLAGL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.86 MEN1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.86 RET MLH1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.86 RET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.86 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.86 MLH1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.86 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.86 PLAG1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.86 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.86 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.86 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.86 RET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.86 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.86 RET
24 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.86 APC CCND1 CTNNB1 KRAS MEN1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.86 APC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.86 MLH1 SMAD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.86 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.86 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.86 CCND1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.86 APC
31 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.86 PLAG1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.86 CCND1 SMAD4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.86 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.86 KRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.86 CCND1 SMAD4 PLAGL2 RET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.86 APC
37 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.86 CCND1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.86 SMAD4
39 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.86 MEN1 SMAD4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.86 SMAD4
41 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.86 CTNNB1 MEN1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.86 CTNNB1 APC KRAS MEN1 PLAG1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.86 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.86 RET
45 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.86 SMAD4
46 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.86 KRAS PLAG1 PLAGL2
47 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.86 CTNNB1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.86 CTNNB1 RET SMAD4 PLAGL2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.86 APC CTNNB1 MLH1 SMAD4
50 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.86 MLH1

MGI Mouse Phenotypes related to Adenoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 CDC73 AIP CCND1 APC GNAS CTNNB1
2 endocrine/exocrine gland MP:0005379 10.46 AIP CCND1 APC CDC73 GNAS CTNNB1
3 growth/size/body region MP:0005378 10.45 CDC73 AIP CCND1 APC GNAS CTNNB1
4 homeostasis/metabolism MP:0005376 10.45 CDC73 AIP CCND1 APC GNAS CTNNB1
5 digestive/alimentary MP:0005381 10.39 CCND1 APC CDC73 CTNNB1 MEN1 LHCGR
6 cardiovascular system MP:0005385 10.38 AIP CCND1 APC CDC73 GNAS CTNNB1
7 behavior/neurological MP:0005386 10.35 APC CCND1 CTNNB1 CDC73 GNAS LHCGR
8 mortality/aging MP:0010768 10.34 AIP CCND1 APC GNAS CTNNB1 CDC73
9 immune system MP:0005387 10.32 APC CCND1 CDC73 GNAS CTNNB1 LHCGR
10 hematopoietic system MP:0005397 10.28 APC CCND1 CTNNB1 CDC73 GNAS LHCGR
11 embryo MP:0005380 10.27 APC AIP CDC73 CTNNB1 KRAS MEN1
12 integument MP:0010771 10.27 CDC73 AIP CCND1 APC GNAS CTNNB1
13 neoplasm MP:0002006 10.21 AIP CCND1 APC CDC73 GNAS CTNNB1
14 craniofacial MP:0005382 10.19 APC CCND1 CTNNB1 CDC73 GNAS KRAS
15 nervous system MP:0003631 10.17 CCND1 APC CDC73 GNAS CTNNB1 KRAS
16 liver/biliary system MP:0005370 10.16 AIP APC CDC73 GNAS CTNNB1 KRAS
17 limbs/digits/tail MP:0005371 10.13 APC GNAS CTNNB1 KRAS LHCGR RET
18 muscle MP:0005369 10.01 APC CTNNB1 CDC73 GNAS KRAS MEN1
19 reproductive system MP:0005389 9.97 CDC73 CCND1 APC CTNNB1 KRAS MEN1
20 renal/urinary system MP:0005367 9.86 APC CTNNB1 CDC73 GNAS LHCGR KRAS
21 respiratory system MP:0005388 9.61 CCND1 CDC73 GNAS CTNNB1 LHCGR KRAS
22 skeleton MP:0005390 9.32 APC CCND1 CTNNB1 CDC73 GNAS LHCGR

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 559)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4 55142-85-3 5472
2
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
3
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2216-51-5 16666
4
Metformin Approved Phase 4,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
6
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
8
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
9
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
10
Ecabet Approved, Investigational Phase 4 33159-27-2, 86408-72-2 65781
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
12
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
13
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
14
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
16
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
17
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Magnesium oxide Approved Phase 4,Phase 2 1309-48-4 14792
20
Magnesium citrate Approved Phase 4,Phase 3,Phase 2 3344-18-1
21
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
22
Methylene blue Approved, Investigational Phase 4,Phase 3 61-73-4
23 lanreotide Approved Phase 4,Phase 3,Phase 2 108736-35-2
24
Bisacodyl Approved Phase 4,Phase 3,Phase 2,Not Applicable 603-50-9
25
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
26
Sodium sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7757-82-6
27
Simethicone Approved Phase 4,Phase 3,Not Applicable 8050-81-5
28
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 23994
29
Sulfamethoxazole Approved Phase 4 723-46-6 5329
30
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
31
Cefazolin Approved Phase 4 25953-19-9 656510 33255
32
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
33
Cefdinir Approved Phase 4 91832-40-5 6915944
34
Liraglutide Approved Phase 4 204656-20-2 44147092
35
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
36
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
37
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
38
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-81-7 5785 54670067
39
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 143 6006
40
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
41
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
42
Butyric Acid Experimental, Investigational Phase 4,Not Applicable 107-92-6 264
43
Lactitol Investigational Phase 4 585-86-4 3871
44 glucagon Phase 4,Early Phase 1
45 Scopolamine hydrobromide Phase 4 114-49-8
46 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 glucocorticoids Phase 4,Phase 2,Phase 1,Not Applicable
48 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49
protease inhibitors Phase 4,Phase 2,Phase 1,Not Applicable
50 Cathartics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1248)
# Name Status NCT ID Phase Drugs
1 Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
3 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
4 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
5 Glucagon and Colonoscopy Unknown status NCT02078726 Phase 4 Glucagon;Placebo
6 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
7 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
8 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
9 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
10 Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies Unknown status NCT01481714 Phase 4 Sodium picosulphate, magnesium oxid and citric acid;Sodium picosulphate/magnesium oxide and citric acid
11 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
12 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
13 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
14 Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy Completed NCT01124266 Phase 4
15 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
16 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT) Completed NCT01607255 Phase 4 Indigo carmine
17 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy Completed NCT02507037 Phase 4 polyethylene glycol
18 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
19 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
20 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
21 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
22 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
23 Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function Completed NCT01810068 Phase 4
24 Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid. Completed NCT02073552 Phase 4 Polyethylene glycol 4000;Macrogol 3350 plus ascorbic acid
25 Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection Completed NCT01887158 Phase 4 Polyethylene glycol;Bisacodyl
26 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
27 Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid Completed NCT02761213 Phase 4 Oral sulfate solution (OSS);2-L PEG/Asc
28 Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps Completed NCT01133041 Phase 4
29 Evaluation of Colonoscopy With a Specific Device for the Detection of Adenomas Recruiting NCT03436004 Phase 4
30 Effect of Simethicone on Screening Colonoscopy Recruiting NCT03119168 Phase 4 Simethicone Solution
31 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Recruiting NCT02032784 Phase 4 octreotide
32 Transanal Endoscopic Microsurgery Versus Endoscopic Submucosal Dissection For Large Rectal Adenomas Recruiting NCT01023984 Phase 4
33 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Recruiting NCT02638584 Phase 4 Ilaprazole;Rabeprazole
34 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
35 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
36 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
37 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
38 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
39 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp Recruiting NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
40 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
41 A Comparison of Eleview Versus Hetastarch as Injectate for EMR Active, not recruiting NCT03350217 Phase 4 Eleview;Hetastarch
42 GreenLight Laser Photoselective Vaporization of the Prostate vs Plasma Kinetic Vaporization of the Prostate; RCT Active, not recruiting NCT02283684 Phase 4
43 Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Not yet recruiting NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
44 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Not yet recruiting NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
45 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Not yet recruiting NCT02832869 Phase 4
46 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Not yet recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
47 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
48 Single Arm Post-marketing Study of SC20 Colonoscope Terminated NCT02279836 Phase 4
49 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
50 Effectiveness of Instillation of Blue Water (Indigo Carmin®) for Colonoscopy Unknown status NCT01937429 Phase 3

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

41
Pituitary, Colon, Thyroid, Lung, Prostate, Salivary Gland, Testes

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 7873)
# Title Authors Year
1
Lipid-poor adrenal adenoma versus metastasis in lung cancer: Diagnosis by "comparative enhancement" at multiphasic MR imaging. ( 29970786 )
2018
2
Primary carcinoma ex-pleomorphic adenoma of anterior commissure of the larynx. ( 29980410 )
2018
3
Family history of colorectal cancer in first-degree relatives and metachronous colorectal adenoma. ( 29463834 )
2018
4
Testosterone- and Cortisol-secreting Oncocytic Adrenocortical Adenoma in the Pediatric Age-group. ( 29426273 )
2018
5
Cripto-1 is overexpressed in carcinoma ex pleomorphic adenoma of salivary gland. ( 29594385 )
2018
6
Superficially Spreading Signet-Ring Cell Carcinoma Perpendicularly Colliding with Gastric Adenoma: a Rare Case Report. ( 29441461 )
2018
7
Lacrimal gland pleomorphic adenoma and malignant epithelial tumours: clinical and imaging differences. ( 29680804 )
2018
8
Associations of Circulating 25-Hydroxyvitamin D3 Concentrations With Incident, Sporadic Colorectal Adenoma Risk According to Common Vitamin D Binding Protein Isoforms. ( 29788105 )
2018
9
A Migratory Mishap: Giant Mediastinal Parathyroid Adenoma. ( 29360437 )
2018
10
Left-Sided Colectomy: One of the Important Risk Factors of Metachronous Colorectal Adenoma After Colectomy for Colon Cancer. ( 29417332 )
2018
11
Histopathologic Features of Colorectal Adenoma and Adenocarcinoma Developing Within Inflammatory Polyps in Miniature Dachshunds. ( 29852840 )
2018
12
Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma-author's reply. ( 29644785 )
2018
13
Improved adenoma detection with Endocuff Vision: the ADENOMA randomised controlled trial. ( 29363535 )
2018
14
Comparison of lymphatic vessel density and expression of VEGF-C and VEGF-D lymphangiogenic factors in Warthin's tumours and oncocytic adenomas. ( 29097817 )
2018
15
Frequency of Mismatch Repair Protein Deficiency in a Puerto Rican Population with Colonic Adenoma and Adenocarcinoma. ( 29976631 )
2018
16
Top 100 Most-Cited Articles on Pituitary Adenoma: A Bibliometric Analysis. ( 29870843 )
2018
17
KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. ( 29016532 )
2018
18
Associations of mitochondrial polymorphisms with sporadic colorectal adenoma. ( 29323753 )
2018
19
Identification, isolation and characterization of human LGR5-positive colon adenoma cells. ( 29467240 )
2018
20
Association of retinal nerve fibre layer thickness with quantitative magnetic resonance imaging data of the optic chiasm in pituitary adenoma patients. ( 29398198 )
2018
21
Association between investigator-measured body-mass index and colorectal adenoma: a systematic review and meta-analysis of 168,201 subjects. ( 29288474 )
2018
22
Clinical and pathological characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. ( 29981466 )
2018
23
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
24
Massive pleural and pericardial effusion due to hypothyroidism in a patient with a surgically treated thyroid-stimulating hormone-producing pituitary adenoma. ( 29757110 )
2018
25
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. ( 29288766 )
2018
26
Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an <i>AIP</i> Mutation-Positive Family. ( 29849625 )
2018
27
Screening of biomarkers for liver adenoma in low-dose-rate gamma-ray-irradiated mice. ( 29424599 )
2018
28
Effect of Xylosyltransferase-I Silencing on Implanting Growth of Salivary Pleomorphic Adenoma. ( 29867072 )
2018
29
Dynamic CT for Parathyroid Adenoma Detection: How Does Radiation Dose Compare With Nuclear Medicine? ( 29629803 )
2018
30
A rare case of atypical pleomorphic adenoma arising from periocular ectopic lacrimal gland. ( 29936687 )
2018
31
Endoanal resection of a giant villous adenoma in the middle rectum - Video Vignette. ( 29364560 )
2018
32
Safety of cold snare polypectomy for duodenal adenomas in familial adenomatous polyposis: a prospective exploratory study. ( 29351704 )
2018
33
Visfatin levels in hormonally inactive adrenal adenoma and their association with metabolic parameters ( 29914251 )
2018
34
Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. ( 29909598 )
2018
35
Pleomorphic adenoma of salivary glands: common and uncommon CT and MR imaging features. ( 29845358 )
2018
36
Artificial neural network model to distinguish follicular adenoma from follicular carcinoma on fine needle aspiration of thyroid. ( 29266871 )
2018
37
Pleomorphic adenoma of the lacrimal gland: A review with updates on malignant transformation and molecular genetics. ( 29755265 )
2018
38
Promoter hypermethylation may contribute to Ea89cadherin repression in the human salivary carcinoma ex pleomorphic adenoma. ( 29207084 )
2018
39
Ceruminous adenoma mimicking otitis externa. ( 29796271 )
2018
40
Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma. ( 29480547 )
2018
41
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. ( 29279316 )
2018
42
The B-ADENOMA Study: Bowelscope - Accuracy of Detection using Endocuff Optimisation of Mucosal Abnormalities: Study Protocol for randomised controlled trial. ( 29978008 )
2018
43
Secreting ectopic adrenal adenoma: A rare condition to be aware of. ( 29525561 )
2018
44
Different effects of metformin and insulin on primary and secondary chemoprevention of colorectal adenoma in diabetes type 2: Traditional and Bayesian meta-analysis. ( 29383018 )
2018
45
Localization of Parathyroid Adenoma Using Contrast-Enhanced Sonography. ( 29781147 )
2018
46
The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. ( 29219920 )
2018
47
Complications after superficial parotidectomy for pleomorphic adenoma. ( 29924764 )
2018
48
A Novel Technology for Localization of Parathyroid Adenoma: Ultrasound-Guided Fine Needle Aspiration Combined With Rapid Parathyroid Hormone Detection and Nano-Carbon Technology. ( 29890904 )
2018
49
Calneuron 1 Increased Ca2+ in the Endoplasmic Reticulum and Aldosterone Production in Aldosterone-Producing Adenoma. ( 29109191 )
2018
50
Epigenetic silencing of<i>SMOC1</i>in traditional serrated adenoma and colorectal cancer. ( 29435136 )
2018

Variations for Adenoma

Expression for Adenoma

Search GEO for disease gene expression data for Adenoma.

Pathways for Adenoma

Pathways related to Adenoma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 APC CCND1 CTNNB1 GNAS KRAS PRL
2
Show member pathways
12.83 AIP APC CCND1 CTNNB1 GNAS KRAS
3
Show member pathways
12.62 APC CCND1 CTNNB1 KRAS MLH1 SMAD4
4
Show member pathways
12.5 APC CCND1 CTNNB1 KRAS MLH1 MSH2
5
Show member pathways
12.4 APC CCND1 CDC73 CTNNB1 SMAD4
6
Show member pathways
12.39 CCND1 KRAS LHCGR PRL
7
Show member pathways
12.37 APC CTNNB1 GNAS SMAD4
8 12.33 APC CCND1 CTNNB1 GNAS KRAS MLH1
9 12.3 APC CCND1 CTNNB1 KRAS SMAD4
10 12.26 APC CCND1 MEN1 SMAD4
11 12.15 APC CDC73 CTNNB1 SMAD4
12 12.05 APC CCND1 CTNNB1 SMAD4
13 12.02 CCND1 CTNNB1 KRAS MSH2 SMAD4
14 11.98 APC CTNNB1 KRAS SMAD4
15 11.86 APC CCND1 CTNNB1 KRAS
16 11.8 CCND1 KRAS SMAD4
17 11.78 APC CCND1 CTNNB1 KRAS SMAD4
18 11.76 CCND1 CTNNB1 SMAD4
19 11.68 APC CCND1 CTNNB1
20 11.48 APC